It's been nearly five years since Moderna (NASDAQ: MRNA) emerged as a biotech industry disruptor, with its COVID-19 vaccine ...
Pfizer and BioNTech won a round in their legal battle with Moderna over COVID-19 vaccine patents on Wednesday, convincing a U.S. Patent Office tribunal that two patents Moderna accused them of ...
The second vaccine, developed by Moderna in partnership with the National Institute of Allergy and Infectious Diseases, got the greenlight from the FDA days later. These steps are now overlapping ...
Shares of the American pharmaceutical company Moderna (MRNA) climbed over 8% in pre-market trading following strategic insider stock purchases ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results